An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations

Trial Profile

An Open-Label Phase 2 Pilot Study Evaluating the Activity and Safety of FP 1039 in Subjects With Advanced and/or Recurrent Endometrial Cancers With Specific FGFR2 Mutations

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2015

At a glance

  • Drugs FP 1039 (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors Five Prime Therapeutics
  • Most Recent Events

    • 09 Mar 2012 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 31 Oct 2011 Additional locations identified as reported by ClinicalTrials.gov.
    • 18 Jan 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top